Compare AbbVie Inc (ABBV) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs EPAM Systems Inc — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while EPAM Systems Inc trades at $87.17 (market cap $4.68B). The key difference: AbbVie Inc is far larger — about 96.1× EPAM Systems Inc's market cap, and AbbVie Inc pays a 2.72% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals.
| ABBV | EPAM | |
|---|---|---|
Market Cap | $449.91B | $4.68B |
Sector | Health | Technology |
52-Week High | $261.07 | $221.40 |
52-Week Low | $184.85 | $76.04 |
Enterprise Value | $513.38B | $3.93B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
EPAM Systems trades at $89.55, up 1.45% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 12.48 and P/S of 0.87, while revenue grew to $5.46B in 2025. Recent news highlights EPAM's AI partnership successes and upcoming Q2 2026 earnings, with analyst consensus strongly favoring Buy ratings (64.87%) and a $130.90 price target suggesting significant upside.
The outlook remains positive given EPAM's solid fundamentals and AI-driven growth, but risks include competitive pressures in IT services and market volatility. Institutional sentiment is bullish, though technical indicators warn of near-term resistance. Investors should weigh the strong analyst support against recent price weakness and sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
